ONCODESIGN Announces the Separation of Its Two Business Line

The planned transactions are as follows: The subsidiarisation by ONCODESIGN of its Biotech/AI activities through a partial transfer of assets to the ONCODESIGN Precision Medicine (OPM) subsidiary

Related Keywords

Saclay , France General , France , United States , Canada , Paris , French , America , Arthur Rouill , Fabrice Viviani , Mathilde Bohin , Olivier Arthaud , Philippe Genne , University Hospital , Garnier Co , Bus Service , Edmond De Rothschild Group , Euronext , Drug Discovery Service , Drug Discovery , Artificial Intelligence , Edmond De Rothschild Equity Strategies , Elyan Partners , Biotech Business Unit , Cabinet Arthaud Associ , Chief Executive Officer , Supervisory Board , French Commercial , Controlling Stake , Control Block , Vincent Man , Maxence De Vienne , Lamy Lexel , Edmond De Rothschild Private Equity , North America , Des March , Private Equity , Euronext Growth Market , Business Units , Relations Arthur Rouill , Oncodesign , Nnounces , Separation , Business , Fines , Service , Biotech , Entry , Into , Exclusive , Negotiations , Ith , Kalyan , Partners , Sale , Majority , Stake , Ollowed , Simplified , Makeover , Offer ,